Sernova Biotherapeutics logo

Sernova Biotherapeutics(TSX) SVA

Market CapCA$43.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-97%
5 Year-91%
1 Year-32%
1 Month+15%
CA$0.12
+0.00%
+0.00Today
Sernova Biotherapeutics last closing stock price
MetricPriceDate
Last closeCAD 0.122026-10-15
Sernova Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%CAD 0.122026-10-08
1 month+15%CAD 0.102026-09-15
3 month+0%CAD 0.122026-07-17
Year to date-11.54%CAD 0.132025-12-31
1 year-32.35%CAD 0.172025-10-15
3 year-84.46%CAD 0.742023-10-16
5 year-91.02%CAD 1.282021-10-15
Since inception-96.81%CAD 3.602000-02-29

Sernova Biotherapeutics Financials at a Glance

Market Cap

CA$43.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$10.29M

EPS (TTM)

-CA$0.03

P/E Ratio

-3.91

Dividend

CA$0.00

Beta (Volatility)

0.43 (Low)

Price

CA$0.12

Volume

15,780

Open

CA$0.11

Previous Close

CA$0.12

Daily Range

CA$0.11 - CA$0.12

52-Week Range

CA$0.09 - CA$0.20

Estimated Earnings Date

Dec 18, 2026

SVA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sernova Biotherapeutics

Sernova Corp. is a Canadian clinical-stage biotechnology company focused on developing innovative regenerative medicine therapies. The company specializes in its proprietary Cell Pouch system, designed to enhance the transplantation and engraftment of therapeutic cells for chronic conditions.

Products and Services
  • Cell Pouch system for localized cellular immune protection
  • Therapeutic cell technologies for chronic conditions
  • Collaborative research with AgeX Therapeutics and the University of Miami
Growth Outlook
  • Partnerships with leading research institutions enhance innovation potential
  • Focus on chronic conditions presents significant market opportunities
  • Advancements in regenerative medicine are gaining industry traction
Financial Highlights
  • Recent quarterly net income of -$2.5 million reflects ongoing R&D investments
  • Trailing twelve months show a consistent focus on innovation despite losses
  • Cash reserves decreased to $63,331, indicating a need for funding
Sernova Corp. operates in a promising sector, leveraging its unique technologies to address unmet medical needs. The company's strategic partnerships and focus on regenerative medicine position it well for future growth. However, recent financial data indicates challenges, including significant net losses and a decrease in cash reserves, which may impact operational capabilities. Investors may find the company's innovative approach and market potential compelling, despite the current financial hurdles.
AI Generated • Oct 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Jonathan M. N. Rigby, MBA

Website

www.sernova.com

Headquarters

Mississauga, ON L5A 4H2, CA

SVA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

57.10%

Return on Capital

N/A

Return on Assets

-2750.96%

Earnings Yield

-25.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$43.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

377.64M

Volume

15.78K

Avg. Volume

212.26K

Financials (TTM)

Gross Profit

-CA$75.51K

Operating Income

-CA$8.90M

EBITDA

-CA$9.01M

Operating Cash Flow

-CA$4.42M

Capital Expenditure

-CA$6.00

Free Cash Flow

-CA$4.42M

Cash & ST Invst.

CA$63.33K

Total Debt

CA$2.58M

Sernova Biotherapeutics Performance Analysis

Sernova Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-10-31CAD 0N/A
20232023-10-31CAD 0N/A
20242024-10-31CAD 0N/A
20252025-10-31CAD 0N/A
Sernova Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-10-31N/A
Q12026-01-31N/A
Q22026-04-30N/A
Q32026-07-31N/A
Sernova Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-10-31CAD -0.09214.4%
20232023-10-31CAD -0.1344.0%
20242024-10-31CAD -0.10-18.4%
20252025-10-31CAD -0.05-54.2%
Sernova Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-10-3146.8%
Q12026-01-31-4.5%
Q22026-04-30-33.3%
Q32026-07-3127.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$4.43K

+97.6%

Gross Margin

0.00%

N/A

Market Cap

CA$43.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$5.43M

N/A

Employees

8

N/A

Net Income

-CA$2.53M

+37.9%

EBITDA

-CA$2.11M

+36.5%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$63.33K

-24.3%

Total Debt

CA$2.58M

-44.9%

Accounts Receivable

CA$10.89K

-95.9%

Inventory

CA$0.00

N/A

Long Term Debt

CA$78.94K

-91.9%

Short Term Debt

CA$2.50M

-32.5%

Return on Assets

-27.51%

N/A

Return on Invested Capital

76.20%

N/A

Free Cash Flow

-CA$989.83K

+52.2%

Operating Cash Flow

-CA$989.83K

+52.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBX.TOMicrobix Biosystems Inc.
CA$0.31+1.64%
MIR.VMedMira Inc.
CA$0.07+0.00%
BCT.TOBriaCell Therapeutics Corp.
CA$5.36+2.10%
RVX.TOResverlogix Corp.
CA$0.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$12.01-7.12%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.32-2.71%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.64+2.63%

Questions About SVA

What is the current price of Sernova Biotherapeutics?

Sernova Biotherapeutics is trading at CA$0.12 per share.

What is the 52-week range for Sernova Biotherapeutics?

Over the past 52 weeks, Sernova Biotherapeutics has traded between CA$0.09 and CA$0.20.

How much debt does Sernova Biotherapeutics have?

As of the most recent reporting period, Sernova Biotherapeutics reported total debt of CA$2.58M.

How much cash does Sernova Biotherapeutics have on hand?

Sernova Biotherapeutics reported CA$63.33K in cash and cash equivalents in its most recent financial results.

What is Sernova Biotherapeutics’s dividend yield?

Sernova Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services